Jun 29, 2021 · 31m · american-optimist
Dr. Rick Klausner: Curing Cancer, Reprogramming Cells, and the Incredible Biotech Revolution · Joe Lonsdale
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of American Optimist, host Joe Lonsdale interviews physician-scientist Dr. Rick Klausner about exponential advances in biotechnology, living cell therapies, and cellular rejuvenation. Dr. Klausner highlights how breakthroughs in gene editing, cell reprogramming, and private venture funding are poised to cure solid tumors and extend human healthspan.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Joe holds 27.9% of the talking time here. How this is scored →
Joe as informed peer 4.6 Guest teaching 3.4 Guest disagreement 0.3 Joe pushing back 0.6
speaking balance: gold is Joe, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 0:55 Rejecting the 'renaissance' terminology
Klausner directly rejects Lonsdale's premise that biology is in a renaissance, pointing out that the field never died to be recovered, but is experiencing a technological hockey stick.
Hardest push from Joe ▶ 16:28 Pushing on FDA favoritism toward big incumbentsLonsdale challenges Klausner's praise of the FDA by presenting peer feedback that the agency defers heavily to large companies while blocking innovative startups.
Biggest teaching moment ▶ 28:33 Correcting the Fountain of Youth explorer and eraKlausner explicitly corrects Lonsdale's historical error when Lonsdale attributes the Fountain of Youth expedition to Vasco da Gama instead of 16th-century Ponce de Leon.
Joe holds their own ▶ 19:30 Demonstrating command of stem cell biology constraintsLonsdale immediately anticipates technical roadblocks by pointing out that Yamanaka factors risk resetting cells to undifferentiated pluripotent stem cells, making whole-organ rejuvenation hazardous without identity retention.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Joe as informed peer | Guest teaching | Guest disagreement | Joe pushing back | Why |
|---|---|---|---|---|---|---|
| The Biological Golden Age and Core Breakthroughs | 3 | 3 | 1 | 0 | Lonsdale asks introductory open-ended questions about whether biology is experiencing a renaissance. Klausner gently reframes the premise, explaining it is not a renaissance but an unprecedented exponential golden age driven by tech convergence. | |
| Cell Therapies, CAR T, and the Three Phases of Medicine | 5 | 4 | 0 | 0 | Klausner outlines the three phases of medicine culminating in living cell therapies. Lonsdale actively synthesizes the concepts accurately, clarifying definitions around small molecules and living cell programming. | |
| Regulatory T Cells and Tackling Solid Tumors | 5 | 3 | 0 | 0 | Lonsdale brings up Sonoma Biotherapeutics and regulatory T cells (Tregs) to guide the discussion. Klausner details the distinction between T effector cells and Tregs in tackling autoimmune disease and solid tumors. | |
| Overcoming Toxicity and the Timeline to End Cancer | 4 | 3 | 0 | 1 | Lonsdale asks specific clinical safety questions regarding CAR T toxicity and cytokine release syndrome. Klausner explains how dosing advances have turned these therapies into manageable outpatient treatments. | |
| Government Basic Science vs. Private Sector Innovation | 6 | 3 | 0 | 1 | Lonsdale displays strong domain awareness, citing Doudna's bacterial research and cell-free DNA in Grail. Klausner shares an anecdote about Joe Biden asking whether the NCI could have built Grail, agreeing with Lonsdale that private venture execution was vital. | |
| Biotech Trial Economics and Working with the FDA | 4 | 2 | 1 | 3 | Lonsdale presses Klausner on FDA bureaucracy, asking whether the agency improperly favors big pharmaceutical incumbents over agile startups. Klausner gently counters that his startups found the FDA highly receptive and collaborative. | |
| Cellular Reprogramming, Yamanaka Factors, and Reversing Aging | 6 | 4 | 0 | 0 | Lonsdale demonstrates sharp technical familiarity with Yamanaka factors, epigenetic memory, and pluripotent stem cells. Klausner details the breakthrough of decoupling cellular rejuvenation from the loss of cell identity. | |
| Healthspan vs. Lifespan and the Pace of Scientific Progress | 4 | 3 | 0 | 0 | The conversation explores lifespan vs healthspan and societal perceptions of scientific progress. Klausner illustrates historical timelines using a personal conversation with Francis Crick on the speed of decoding DNA. | |
| Evaluating Biotech Investments and Avoiding False Science | 4 | 6 | 1 | 0 | Klausner explains how investors must differentiate deep biology from superficial anti-aging claims. When Lonsdale mistakenly attributes the Fountain of Youth to Vasco da Gama, Klausner directly corrects the historical reference to Ponce de Leon. |
Statements from this episode (17)
Klausner: Life sciences will drive the 21st century across all industries
“We're at what I think will be viewed as truly a revolutionary golden age in life sciences, which is going to have impacts on everything. Not only we think about it as health, but it's going to change how we think about manufacturing the environment chemistry. …”
Klausner: DNA manipulation and AI convergence are biology's key breakthroughs
“I think the most important breakthroughs has been the ability to read and write DNA. The new ability to actually manipulate and edit DNA. And then I think the convergence of tech and computational sciences and artificial intelligence, machine learning with bio…”
Klausner: CAR T therapies from Juno and Kite cure end-stage blood cancers
“Over the last five years, through a number of companies in particular, such as Juno, Kite, Novartis, there are now drugs on the market that are curing people with end stage incurable Hematologic malignancies like lymphoma, leukemia, myeloma, with this now one-…”
Klausner: Living cell therapies represent the third phase of scientific medicine
“I think we're at the very beginning of the third, maybe even final phase, of scientific therapies, Which are living cells as drugs.”
Klausner: Next breakthrough will be curative T-cell therapy for solid tumors
“So I think the next big breakthrough in, in curative therapy is going to be curative therapy for any solid tumor by getting these T cells to have the properties that allow them to stay active even in solid tumors, which have the ability, maybe why they exist, …”
Klausner: Juno Engineered CAR T Therapies Administered to Outpatients
“With Juno, we were able to make these CAR T cells where almost everyone is treated as an outpatient. They don't even have to go into the hospital.”
Klausner: Upcoming Patient Trials Could Signal Beginning of End of Cancer
“It's going to be tried in patients over the next year or so. If we were right scientifically, I think we can be thinking about seeing the beginning of the end of cancer.”
Klausner: Government must fund basic science while business translates it
“I think the right role for government in this sort of science is to support very undifferentiated basic science. That's the, that sort of is the foundation for now the ability to create Entities that are really good at taking that and turning them into medicin…”
Klausner: GRAIL required $1.5B+ in private capital over four years
“And turns out we learned over about four years with over a billion and a half dollars of private investment to figure that out.”
Klausner: The National Cancer Institute could not have created GRAIL
“And he asked me explicitly, could you have done that if you were still running the National Cancer Institute? And I believe the answer is no. It's extremely hard to aggregate all of those resources and to create the type of completely mission-driven venture.”
Klausner: GRAIL clinical trials enrolled over 150,000 participants
“For GRAIL, we had clinical trials that involved over a 150,000 participants, and those are really expensive.”
Klausner: FDA engaged quickly and helped biotech startups with cell therapy
“I mean, with companies that I've started, we engage the FDA very quickly. They're interested in the science and they, you know, like with cell therapy, they were incredibly helpful.”
Klausner: Cellular Rejuvenation Would Be Humanity's Biggest Medical Revolution
“Cells are able to do that and the ability to imagine understanding and controlling that would be the biggest revolution in medicine, health, maybe even society that humanity has ever experienced.”
Klausner: Scientists Can Reset Cell Age Without Losing Identity
“Over the last few years, a number of scientists have figured out amazingly how to manipulate the Yamanaka factors to dissociate the resetting of the age clock
From the loss of cell identity.”
Klausner: Rejuvenated Cells Reset to Ages 12 to 20
“The early studies actually suggest that when you rejuvenate cells this way,
They sort of go back to the end of development, sort of the, you know, around 15, you know, 12 to 20, somewhere between puberty and the end of development, and there seems to be a litt…”
Klausner: Cells Can Be Rejuvenated in Days, Enabling Rapid Trials
“We can rejuvenate cells in a couple of days, and as we learn to measure what this, quote, young, healthy cell looks like. It's not about having to ask whether people don't age as much over four decades. It's about the types of measurements that we can do with …”